F Jiao1, C K H Wong1, S C W Tang2, C S C Fung1, K C B Tan2, S McGhee3, R Gangwani4, C L K Lam1. 1. Department of Family Medicine and Primary Care, University of Hong Kong, Ap Lei Chau, Hong Kong. 2. Department of Medicine, University of Hong Kong, Ap Lei Chau, Hong Kong. 3. School of Public Health, University of Hong Kong, Ap Lei Chau, Hong Kong. 4. Department of Ophthalmology, University of Hong Kong, Ap Lei Chau, Hong Kong.
Abstract
AIM: To develop models to estimate the direct medical costs associated with diabetes-related complications in the event year and in subsequent years. METHODS: The public direct medical costs associated with 13 diabetes-related complications were estimated among a cohort of 128 353 people with diabetes over 5 years. Private direct medical costs were estimated from a cross-sectional survey among 1825 people with diabetes. We used panel data regression with fixed effects to investigate the impact of each complication on direct medical costs in the event year and subsequent years, adjusting for age and co-existing complications. RESULTS: The expected annual public direct medical cost for the baseline case was US$1,521 (95% CI 1,518 to 1,525) or a 65-year-old person with diabetes without complications. A new lower limb ulcer was associated with the biggest increase, with a multiplier of 9.38 (95% CI 8.49 to 10.37). New end-stage renal disease and stroke increased the annual medical cost by 5.23 (95% CI 4.70 to 5.82) and 5.94 (95% CI 5.79 to 6.10) times, respectively. History of acute myocardial infarction, congestive heart failure, stroke, end-stage renal disease and lower limb ulcer increased the cost by 2-3 times. The expected annual private direct medical cost of the baseline case was US$187 (95% CI 135 to 258) for a 65-year-old man without complications. Heart disease, stroke, sight-threatening diabetic retinopathy and end-stage renal disease increased the private medical costs by 1.5 to 2.5 times. CONCLUSIONS: Wide variations in direct medical cost in event year and subsequent years across different major complications were observed. Input of these data would be essential for economic evaluations of diabetes management programmes.
AIM: To develop models to estimate the direct medical costs associated with diabetes-related complications in the event year and in subsequent years. METHODS: The public direct medical costs associated with 13 diabetes-related complications were estimated among a cohort of 128 353 people with diabetes over 5 years. Private direct medical costs were estimated from a cross-sectional survey among 1825 people with diabetes. We used panel data regression with fixed effects to investigate the impact of each complication on direct medical costs in the event year and subsequent years, adjusting for age and co-existing complications. RESULTS: The expected annual public direct medical cost for the baseline case was US$1,521 (95% CI 1,518 to 1,525) or a 65-year-old person with diabetes without complications. A new lower limb ulcer was associated with the biggest increase, with a multiplier of 9.38 (95% CI 8.49 to 10.37). New end-stage renal disease and stroke increased the annual medical cost by 5.23 (95% CI 4.70 to 5.82) and 5.94 (95% CI 5.79 to 6.10) times, respectively. History of acute myocardial infarction, congestive heart failure, stroke, end-stage renal disease and lower limb ulcer increased the cost by 2-3 times. The expected annual private direct medical cost of the baseline case was US$187 (95% CI 135 to 258) for a 65-year-old man without complications. Heart disease, stroke, sight-threatening diabetic retinopathy and end-stage renal disease increased the private medical costs by 1.5 to 2.5 times. CONCLUSIONS: Wide variations in direct medical cost in event year and subsequent years across different major complications were observed. Input of these data would be essential for economic evaluations of diabetes management programmes.
Authors: Fangfang Jiao; Eric Yuk Fai Wan; Colman Siu Cheung Fung; Anca Ka Chun Chan; Sarah Morag McGhee; Ruby Lai Ping Kwok; Cindy Lo Kuen Lam Journal: Endocrine Date: 2018-08-28 Impact factor: 3.633
Authors: Eric Yuk Fai Wan; Esther Yee Tak Yu; Weng Yee Chin; Daniel Yee Tak Fong; Edmond Pui Hang Choi; Eric Ho Man Tang; Cindy Lo Kuen Lam Journal: J Am Soc Nephrol Date: 2019-09-06 Impact factor: 10.121
Authors: Tingting Wu; Fan Yang; Wendy Wing Lok Chan; Cindy Lo Kuen Lam; Carlos King Ho Wong Journal: J Diabetes Investig Date: 2020-07-16 Impact factor: 4.232
Authors: Kam Wa Chan; Alfred Siu Kei Kwong; Pun Nang Tsui; Simon Chi Yuen Cheung; Gary Chi Wang Chan; Wing Fai Choi; Wai Han Yiu; Yanbo Zhang; Michelle Man-Ying Wong; Zhang-Jin Zhang; Kathryn Choon Beng Tan; Lixing Lao; Sydney Chi Wai Tang Journal: BMJ Open Date: 2021-01-12 Impact factor: 2.692
Authors: Jian-Jun Li; Khung Keong Yeo; Kathyrn Tan; Junya Ako; Rungroj Krittayaphong; Ru San Tan; Philip E Aylward; CarolynS P Lam; Sang Hong Baek; Jamshed Dalal; Alan Fong; Yi-Heng Li; Richard C O'Brien; Si Ya Natalie Koh; Daniel J Scherer; Hayato Tada; Vernon Kang; Julie Butters; Stephen J Nicholls Journal: Am J Prev Cardiol Date: 2020-11-08